Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297346 | 1.00 | MAOB (0.59) | MAOBMMP13TNKS2MAOATP53 | |
| SCHEMBL2299358 | 1.00 | MAOB (0.59) | MAOBMMP13TNKS2MAOATP53 | |
| SCHEMBL19586198 | 0.82 | MAOB (0.55) | MAOBMMP13TNKS2MAOATP53 | |
| SCHEMBL7914440 | 0.80 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4485789 | 0.80 | PRKAB2 (0.47) | MAOB | |
| SCHEMBL4485781 | 0.80 | PRKAB2 (0.47) | MAOB | |
| SCHEMBL28763805 | 0.79 | MAOB (0.57) | MAOB | |
| SCHEMBL8481310 | 0.77 | LMNA (0.55) | MAOBMAOATP53 | |
| SCHEMBL8483583 | 0.77 | LMNA (0.55) | MAOBMAOATP53 | |
| SCHEMBL3004785 | 0.77 | LMNA (0.55) | MAOBMAOATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662337-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-05-30 | — | — | US | disclosed |
| US-9662337-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-05-30 | — | — | US | disclosed |
| US-9662337-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-05-30 | — | — | US | disclosed |
| US-20160151376-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| US-20160151376-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| US-20160151376-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| EP-2590954-B1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2016-04-13 | — | — | EP | disclosed |
| EP-2590954-B1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2016-04-13 | — | — | EP | disclosed |
| US-9273017-B2 | (Thio)morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LIMITED (BS) | 2016-03-01 | — | — | US | disclosed |
| US-9273017-B2 | (Thio)morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LIMITED (BS) | 2016-03-01 | — | — | US | disclosed |
| US-20130203745-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-08 | — | — | US | disclosed |
| EP-2590954-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-05-15 | — | — | EP | disclosed |
| US-20120220552-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BAHAMAS LIMITED (BS) | 2012-08-30 | — | — | US | disclosed |
| US-20120220552-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BAHAMAS LIMITED (BS) | 2012-08-30 | — | — | US | disclosed |
| US-20120220552-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BAHAMAS LIMITED (BS) | 2012-08-30 | — | — | US | disclosed |
| EP-2473490-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | Abbott Healthcare Products B.V. (NL) | 2012-07-11 | — | — | EP | disclosed |
| WO-2012004375-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004375-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011023795-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011023795-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220552-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | MAOB 1842/4885MMP13 4360/4885TNKS2 4297/4885 |
| US-20130203745-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | MAOB 1390/4885MMP13 4479/4885TNKS2 4177/4885 |
| US-20160151376-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR1, S1PR3, S1PR2 | MAOB 3022/4885MMP13 3988/4885TNKS2 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.